leisure time -WSS

leisure time

author：knowledge 2025-10-02 14:38:57 - browse：41179

Liver illustration — Hyacinth Empinado/STAT

SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.

GLP-1 treatments, such as Ozempic and Mounjaro, are a class of drugs that have grown widely popular for their efficacy not only in lowering blood sugar, but also cutting weight. Drugmakers have started to study them in liver disease, and while some trials have shown they may offer some benefits, they haven’t yet been shown to improve harmful liver scarring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： A new drug could help frostbite victims avoid its ravages

focus

WSS

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Flagship Pioneering startup Sonata Therapeutics lays off 21

Oak trusses raised to roof of fire

Palantir health business leans on meeting customers’ needs

Reporting on presidential health from Reagan to Trump and Biden

hotspot

leisure time

focus

Peter Hotez and the public health issue of online harassment

Lecanemab for Alzheimer's is coming. Is the health system ready?

At least 13 dead in Texas as scorching temps continue

Why ADHD is under

Alkermes shareholders re

New study raises questions about niacin and heart health

Malaria cases in Florida and Texas: Here’s what you need to know

Oak trusses raised to roof of fire

Supreme Court strikes down use of affirmative action

Elizabeth Holmes on track for early release from her 11

focus

MD Anderson's Padmanee Sharma responds to research credit suit

Lecanemab for Alzheimer's is coming. Is the health system ready?

Lecanemab for Alzheimer's is coming. Is the health system ready?

As AI regulations shape up, health tech startups beg for clarity

New CMS data security rules will hurt Medicare, Medicaid research

Researchers tackle phage therapy hurdles for wider adoption

knowledge

knowledge

explore

focus